The Effects of Memantine on Cognitive Function and Pain after Sevoflurane and Desflurane Anesthesia in Streptozotocin Induced Diabetic Rats

Streptozosin Uygulanan Diyetetik Ratlarda Memantin Kullanımının Sevoflurani ve Desfluran Anestezisi Sonrası Kognitif Fonksiyonlar ve Ağrı Üzerine Etkileri

Ünal Taş, Mehmet Akçabay, Mustafa Arslan, Yusuf Ünal

Department of Anesthesiology and Reanimation, Gazi University, School of Medicine, Ankara, Turkey

ABSTRACT

Objective: Postoperative cognitive dysfunction (POCD) refers to a wide range of alterations which effect memory, information processing and executive function after anesthesia and, the mechanism is still not properly defined. Diabetes is a chronic metabolic disease which has a negative impact on cognitive function and leads to impairment of perception of pain by causing peripheral neuropathy. Sevoflurane and desflurane are anesthetic agents which are shown to cause POCD in many studies. Memantine is an agent which has a positive contribution on memory and learning; also known as neuroprotective and used in chronic pain treatment. In this study, we aim to investigate the effects of memantine, after sevoflurane and desflurane anaesthesia on cognitive function and pain levels in diabetic rats.

Materials and Methods: In our study, we used 42, old (>12 months) Wistar Albino rats, 6 of them were grouped as control group (Group C). We have injected 55 mg/kg streptozotocin (i.p) in the other wistar rats and measured blood glucose and weight. Diabetic 36 rats were randomized into 6 groups (n=6) and groups were defined as Group DC, Group DM, Group DS, Group DD, Group DDM and control group Group C. During 30 days we added 20 mg/kg memantine into the drinking water of Group DM, Group DSM and Group DDM’s rats. We measured radial arm maze (RAM) and hot plate values of 30 days-long period and after that we measured 0.1 and 2 hours RAM and hot plate values of this rats and other rats.

Results: In the groups of which only variant was diabetes (until the study day Group C and Group DC, Group DS and Group DD, groups which weren’t given memantine), we compared the results and we conclude that diabetes has negative impact on cognitive function. Similarly, in the groups of which only variant was sevoflurane (Group DS and Group DC) or was desflurane (Group DD and Group DC) we compared the results and we conclude that our inhaler agents effect cognitive functions negatively. And yet, in the groups of which only variant was just inhaler agents (Group DS and Group DD; Group DDM and Group DDM), inhaler agents have similar effects on cognitive function and recovery. And finally, in the rat groups of which only variant was memantine (Group DC and Group DM, Group DSM and Group DDM and Group DD), we observe that memantine fasten recovery time and has a positive effects on cognitive functions.

Conclusion: In conclusion, administration of memantine in diabetic rats has positive effect on recovery, cognitive functions and pain levels after anesthesia with sevoflurane or desflurane.

Key Words: Memantine, desflurane, sevoflurane, diabetes mellitus, RAM, POCD, hot plate

Anahtar Sözcükler: Memantin, desfluran, sevoflurani, diabetes mellitus, RAM, POKD, hot plate

Received: 06.17.2017
Accepted: 08.10.2017
Geleş Tarihi: 17.06.2017
Kabul Tarihi: 10.08.2017

ORCID IDs: Ü.İ. 0000-0001-7440-8971, M.A. Emekli, M.A.0000-0003-4882-5063, Y.Ü. 0000-0001-6260-5177

Address for Correspondence / Yazışma Adresi: Mustafa Arslan, MD, Department of Anesthesiology and Reanimation, Gazi University, School of Medicine, Ankara, Turkey

E-mail: mustarlasan@gmail.com

©2020 Gazi Üniversitesi Tıp Fakültesi - Makale metnine http://medicaljournal.gazi.edu.tr/ web adresinden ulaşılabilir.

Copyright 2020 by Gazi University Medical Faculty - Available on-line at web site http://medicaljournal.gazi.edu.tr/
doi:http://dx.doi.org/10.12996/gmj.2020.35
INTRODUCTION
Postoperative cognitive dysfunction (POCD) is defined as postoperatively –also following anesthesia- emerged regression of cognitive functions such as memory, ability of concentration, language and social communication skills. Frequency of POCD is varied between 33% and 83% (1). POCD may be continued for hours, days, weeks or can result in permanent cognitive dysfunction (2, 3).

Diabetes Mellitus (DM) is a well-known risk factor for cardiovascular diseases, blindness, renal failure. Also DM leads structural damage and subsequent cognitive dysfunction in central nervous system (CNS) (4).

Memantine is a N-methyl D aspartate (NMDA) receptor antagonist that its effectiveness on Alzheimer disease has been proven. Previous studies have shown that memantine can reverse changes in memory disturbances and synaptic plasticity in animal models (5). Also there are several pre-clinical and clinical studies indicate positive effects of memantine on learning capability and memory function (6, 7). On the other hand positive effects of memantine on pain management has been reported (8).

In the present study effects of memantine on recovery, cognitive functions and pain management after sevoflurane or desflurane anesthesia in streptozotocin (STZ) induced diabetic rats was investigated. We aimed to eliminate inhibitory activity of sevoflurane or desflurane on CNS using memantine's effect on glutamate pathway. We used Radial Arm Maze (RAM) test and hot plate tests on rats in order to evaluate cognitive functions and pain levels respectively.

MATERIALS and METHODS
Animals and experimental protocol
This study was conducted in the GUDAM Laboratory of Gazi University with the consent of the Experimental Animals Ethics Committee of Gazi University (G. Ü. ET. 13.084). All animals received human care in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and the Use of Laboratory Animals” prepared by the National Academy of Science and published by the National Institutes of Health (NIH publication Nr. B5–23, revised in 1985).

We used 42 Wistar Albino old rats (>12 months) weighing between 150-200 g. Rats were housed under controlled conditions of light cycle (12 hours:12 hours light:dark) with free access to water and rat chow. The study day study animals were fastened before night. Before studying the experiment blood glucose levels and body weights of all animals were measured. 6 rats were control group (Group C) and in this group diabetes were not induced. Other 36 rats were randomly divided into 6 study groups (Group DC, Group DM, Group DS, Group DD, Group DSM and Group DDM).

Group C (Control Group): Rats were allowed free access to water and chow for 30 days, RAM and hot plate values were measured weekly. At the 31th day of experiment number and duration of entrance/exit and hot plate times at 0, 1 and 2nd hours were recorded as measured in other groups.

Group DM (Diabetes Memantine Group): Memantine (20 mg/kg/day) (Ebixa® Lundbeck îçl. Tic. Ltd. Str, İstanbul, Türkiye) was added in drinking water of rats for 30 days. Daily water consumption of rats were adjusted as 10-12 ml/100 gr body weight. Drinking water was refreshed weekly. RAM and hot plate values were determined weekly. At the 31th day of experiment, number and duration of entrance/exit and hot plate times at 0, 1 and 2nd hours were recorded as measured in other groups.

Group DS (Diabetes Sevoflurane Group): RAM and hot plate values were determined weekly. At the 31th day of experiment, rats were given 1 MAC of sevoflurane 2% (Sevorane 250 ml, Abbott, İstanbul, Türkiye) (100% oxygen mixture at 4 L/min flow rate) for 2 hours in a bell jar with a gas entrance/exit hole. Recovery time after anesthesia, number and duration of entrance/exit and hot plate times at 0, 1 and 2nd hours were recorded.

Group DD (Diabetes Desflurane Group): RAM and hot plate values were determined weekly. At the 31th day of experiment, rats were given 1 MAC of desflurane 6% (Suprane 240 ml, Baxter) (100% oxygen mixture at 4 L/min flow rate) for 2 hours in a bell jar with a gas entrance/exit hole. Recovery time after anesthesia, number and duration of entrance/exit and hot plate times at 0, 1 and 2nd hours were recorded.

Group DSM (Diabetes Sevoflurane Memantine Group): Memantine (20 mg/kg/day) was added in drinking water of rats for 30 days. Daily water consumption of each rat was adjusted as 10-12 ml/100 gr body weight. Drinking water was refreshed weekly. RAM and hot plate values were determined weekly. At the 31th day of experiment, rats were given 1 MAC of sevoflurane 2% (100% oxygen mixture at 4 L/min flow rate) for 2 hours in a bell jar with a gas entrance/exit hole. Recovery time after anesthesia, number and duration of entrance/exit and hot plate times at 0, 1 and 2nd hours were recorded.

Group DDM (Diabetes Desflurane Memantine Group): Memantine (20 mg/kg/day) was added in drinking water of rats for 30 days. Daily water consumption of each rat was adjusted as 10-12 ml/100 gr body weight. Drinking water was refreshed weekly. RAM and hot plate values were determined weekly. At the 31th day of experiment, rats were given 1 MAC of desflurane 6% (100% oxygen mixture at 4 L/min flow rate) for 2 hours in a bell jar with a gas entrance/exit hole. Recovery time after anesthesia, number and duration of entrance/exit and hot plate times at 0, 1 and 2nd hours were recorded.

Statistical Analysis
Statistical analysis was performed using SPSS 20.0 packet program. Data was expressed as mean±standard deviation (SD). p<0.05 was determined as statistically significant.

Shapiro-Wilk test was used in order to determine normal/abnormal distribution of measured parameters. One-way ANOVA test was used to determine intergroup differences between normally distributed data in groups. Significant differences between groups were compared using Bonferroni test.

Repeated data from hot plate and entry-exit to RAM tests were analyzed using Repeated measures analysis of variance (rANOVA) test. Certain time points which significant differences identified were determined using Bonferroni correction.

RESULTS
Weights of rats in all groups before and after induced diabetic state were similar (p>0.05), (Table 1).

Table 1. Mean body weights of rats in study groups (Mean ± SD).

| Weight (g) | Group C (n=6) | Group DC (n=6) | Group DM (n=6) | Group DS (n=6) | Group DD (n=6) | Group DSM (n=6) | Group DDM (n=6) | P |
|-----------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---|
| Baseline  | 172,83±11,55  | 179,66±11,25  | 168,67±20,73  | 178,00±10,79  | 170,33±16,43  | 171,83±14,68  | 177,50±19,10  | 0,844 |
| End of study | 193,17±10,99  | 184,50±11,78  | 160,17±20,16  | 194,00±10,64  | 186,33±25,18  | 191,23±25,92  | 187,67±35,42  | 0,149 |

p value: achieved from multiple comparisons

Blood glucose levels of diabetic rats were significantly higher than those measured in non-diabetics (p<0.0001), (Table 2).
between Group DSM and Group DS. Values measured in Group DDM were significantly higher than those measured in Group DC. Similarly values in Group DSM were significantly higher than those measured in Group DS. Control Group (Group C) and Diabetic Control Group (Group DC). Hot plate values in Group DS and Group DD were lower than those measured in Group DM.

Table 3. Mean hot plate values of study groups [Mean ± SD].

| Hot plate values | Group C (n=6) | Group DC (n=6) | Group DM (n=6) | Group DS (n=6) | Group DD (n=6) | Group DDM (n=6) | Group DSM (n=6) | P      |
|-----------------|--------------|---------------|---------------|---------------|---------------|---------------|---------------|--------|
| 1. week         | 8.83±1.94    | 10.00±1.26    | 8.33±1.86     | 10.83±2.92    | 8.16±0.41     | 8.67±1.75     | 10.17±0.98    | 0.080  |
| 2. week         | 7.50±1.22    | 9.17±0.75     | 12.83±1.55*   | 11.83±0.75    | 9.33±1.26     | 12.50±2.17*   | 13.17±2.04*   | <0.0001|
| 3. week         | 8.33±1.86    | 11.50±1.76    | 14.50±1.38*,+ | 11.83±2.48    | 10.83±0.98    | 15.00±1.76*   | 13.50±1.05*,= | <0.0001|
| 4. week         | 10.33±1.21   | 10.17±1.47    | 17.50±2.66*,= | 12.83±2.56    | 11.83±1.76&   | 15.67±1.37*,= | 16.67±1.97*,|=   | <0.001 |
| 0. hour         | 10.50±1.05   | 11.33±2.25    | 15.83±1.17*,= | 19.00±2.61*,= | 15.67±1.37*,= | 25.00±0.00*,= | 20.66±0.82*,= | <0.0001|
| 1. hour         | 10.50±0.55   | 13.17±0.75*   | 15.33±1.60*,= | 16.83±1.60*,= | 12.67±1.20*   | 23.67±1.64*,= | 18.67±1.21*,= | <0.0001|
| 2. hour         | 10.67±2.16   | 12.50±4.50    | 15.00±4.47*,= | 15.17±1.47*   | 13.33±2.42*   | 19.50±1.52*,= | 16.67±0.65*,= | 0.005  |

p value: achieved from multiple comparisons
*: p<0.05 (when compared with Group C), #: p<0.05 (when compared with Group DC), &: p<0.05 (when compared with Group DM), ?: p<0.05 (when compared with Group DD), **: p<0.05 (when compared with Group DS), =: p<0.05 (when compared with 1. week).

Hot plate values measured at 0th hour after desflurane or sevoflurane administration in Group DM, Group DD, Group DDM and Group DSM were significantly higher than that in Group C. Similarly when compared with Group DC, values measured in those groups were found significantly higher. Additionally hot plate values measured at 0th hour after desflurane or sevoflurane administration in Group DM and Group DSM were significantly higher than that in Group DD. Also values measured in Group DDM were higher than that measured in Group DD. Similar results were found between Group DSM and Group DS. Hot plate values measured at 1st hour after desflurane or sevoflurane administration in all study groups –except Group DC- were significantly higher than that measured in Group C. Additionally values in Group DMM were significantly higher than those measured in Group DM.

Within group comparisons of hot plate values revealed that values at all time points in Group C and Group DC were similar with baseline values. Values measured 0th hour after anesthesia in Group DD were higher than baseline values. In Group DS, values measured at 0th and 1st hours were significantly higher than baseline values. Hot plate values measured at all time points -except 2nd week- in all memantine treated groups were significantly higher than baseline values. Mean entry-exit numbers 1st week after diabetes induction were similar between all study groups. The mean numbers 2nd week after diabetes induction in all study groups were significantly lower than those measured in control group. Mean numbers at 3rd and 4th weeks in Group DC, Group DD and Group DS were significantly lower than those recorded in control group. Results in all memantine treated groups were similar with control group (Table 4).
Mean entry-exit numbers at 0\textsuperscript{th}, 1\textsuperscript{st} and 2\textsuperscript{nd} hours in Group DC, DD and DS were lower than those measured in Group C. Mean numbers recorded at 0\textsuperscript{th} and 1\textsuperscript{st} hours in Group DSM were lower than those measured in Group C.

Mean entry-exit numbers at 0\textsuperscript{th} hour in Group DD were lower than Group DC. Mean entry-exit numbers at 0\textsuperscript{th} and 1\textsuperscript{st} hours in Group DS were lower than Group DC. Mean entry-exit numbers at 0\textsuperscript{th} and 1\textsuperscript{st} hours in Group DD were lower than Group DC.

Mean entry-exit numbers at 0\textsuperscript{th}, 1\textsuperscript{st} and 2\textsuperscript{nd} hours in Group DD and Group DS were lower than those measured in Group DM. Mean entry-exit numbers at 0\textsuperscript{th} hour in Group DDM and Group DSM were significantly lower than those measured in Group DM.

Mean entry-exit numbers at 0\textsuperscript{th} hour in Group DSM were significantly higher than those measured in Group DD. Similarly mean numbers at 0\textsuperscript{th} hour in Group DDM were higher than those measured in Group DS.

**DISCUSSION**

In this study we observed positive effects of memantine – a NMDA receptor antagonist- on postoperative recovery, cognitive functions and acute pain after sevoflurane or desflurane anesthesia in streptozocin induced diabetic rats.

We found significantly decreased RAM entrance-exit numbers after 2\textsuperscript{nd} week in diabetic rats (Group DC, Group DS and Group DD) when compared with Control Group (non-diabetic and untreated group). This result indicates that diabetes induces cognitive dysfunction and memory disturbances in rats. There are contrary reports related with correlation between diabetes and cognitive functions \cite{9,10}. However many of these studies showed lower word fluency, verbal and auditory learning performance in diabetics when compared with normal controls \cite{11,12}. In general, diabetes may negatively affect perception and lead Alzheimer or dementia-like clinical outcomes. The results of present study –that investigates cognitive functions in diabetic rats are compatible with previous studies conducted with diabetic animals.

We observed negative effects of inhalation agents on cognitive functions using results of RAM settings. We found similar levels of POCD after sevoflurane or desflurane anesthesia. However according to our results we can not make any certain implication regarding superiority of these agents to each other. Anesthetic agents did not determined in circulation several days after operations however its thought that these agents present much longer periods in CNS and so they may induce structural changes in CNS. Several animal and laboratory experiments showed inhalation anesthetic induced POCD via resulting increased levels of oligomerization of Alzheimer related peptides and subsequent cytotoxicity \cite{13,14}.

Agents used in Alzheimer disease target cholinergic and glutamatergic pathways. Although effects of these agents on pathogenesis are unclear, they are useful in symptomatic relief. Memantine is a non-competitive NMDA antagonist that targets the glutamatergic system. Memantine can be used in patients with moderate to severe Alzheimer diseases with cognitive and behavioral dysfunction. The drug was approved from FDA for indications mentioned above (15). Due to its positive effects on learning processes and memory of patients with Alzheimer disease also proven neuroprotective and anagelse effects, we postulated that memantine may have positive effects on POCD and acute postoperative pain. Because of the single form that clinically accessible is oral form, we used oral form of memantine (Ebixa\textsuperscript{®}) and so results of our study can be adapted to clinical studies.

Minkeviciene et al. \cite{6} showed increased learning capability and memory following 3 weeks of memantine treatment (30 mg/kg/day) in APP and PS1 gen mutated old (8 months) mice. Authors added memantine in drinking water and evaluated cognitive functions using Morris water tank model. They observed increased results in Morris water tank model however they couldn't show any effects of memantine on locomotor activity (swimming ability in water tank etc.) Wise et al. \cite{16} investigated effects of different memantine doses ( low dose - 0.3 vs 0.56 mg/kg i.p. and high dose 3 vs 10 mg/kg i.p.) on learning capability and memory using RAM model in old male rats (12-16 months). Low doses of memantine was found related with -0.3 and 0.56 mg/kg i.p. decreased number of entrance-exit and improved memory. In contrast RAM results were deteriorated in high dose groups. In 3 mg/kg treated group; only 1 rat entered both of 8 limbs, another one entered 4 limbs while others did not enter/exit to limbs. In 10 mg/kg memantine treated group none of the rats entered limbs. The authors concluded that effects of memantine on cognitive functions are dose dependent.

In another study Zajaczkowski et al. \cite{17} compared effects of a newly developed NMDA receptor antagonist (+)-5-Methyl-10,11-dihydro-SH-dibenozklohepten-5,10-imine maleate (MK-801) and memantine on cognitive functions of normal rats and rats with damaged cortex -which mimics Alzheimer disease-. In order to achieve certain serum and blood concentration, both of agents were administered via subcutaneously. Authors observed negative effects of MK-801 (0.312 mg/kg/day) on learning capability of normal rats. In contrast memantine (20 mg/kg/day) was found in relation with reversal of damage induced memory loss and augmentation of cognitive dysfunction.

**Table 4. Mean number of Radial Arm Maze (RAM) entry-exit of study groups \([\text{Mean} \pm \text{SD}]\).**

| Radial Arm Maze (entry-exit) | Group C \((n=6)\) | Group DC \((n=6)\) | Group DM \((n=6)\) | Group DS \((n=6)\) | Group DD \((n=6)\) | Group DSM \((n=6)\) | Group DDM \((n=6)\) | P       |
|-----------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|---------|
| 1.week                      | 10.00±0.63     | 9.67±1.03     | 10.50±2.07     | 12.71±2.40     | 11.00±2.19     | 10.83±2.23     | 10.17±2.32     | 0.396    |
| 2. week                     | 8.00±1.55      | 5.50±1.22*    | 5.83±0.75*     | 5.83±0.42*     | 5.83±0.75*     | 6.00±0.63*     | 6.00±0.63*     | 0.001    |
| 3. week                     | 8.50±0.50      | 5.50±0.55*    | 7.67±2.50      | 6.67±1.57*     | 7.00±1.10*     | 8.50±1.05*     | 9.50±0.55*     | <0.0001  |
| 4. week                     | 6.33±0.52      | 4.33±0.52*    | 5.50±0.55      | 5.17±0.41*     | 4.50±0.84*     | 5.33±0.52      | 5.17±1.72      | 0.006    |
| 0.hour                      | 6.67±1.02      | 2.43±0.82*    | 7.00±1.55+     | 1.50±0.55*,+,= | 1.00±0.63*,+,= | 3.67±0.52*,+,= | 3.17±0.41*,+,= | <0.0001  |
| 1.hour                      | 6.83±0.75      | 4.50±0.55*    | 6.00±0.63+     | 3.00±0.89*,+,= | 3.67±1.03*,+,= | 3.33±0.52*,     | 4.67±0.52*     | <0.0001  |
| 2.hour                      | 7.00±1.03      | 4.33±1.21*    | 6.00±1.26      | 4.50±0.55*,=   | 4.33±0.82*,=   | 5.50±0.84      | 5.67±1.02      | <0.0001  |

*p value: achieved from multiple comparisons*

*: p<0.05 (when compared with Group C), #: p<0.05 (when compared with Group DC), &: p<0.05 (when compared with Group DM), ?: p<0.05 (when compared with Group DD), **: p<0.05 (when compared with Group DS), +: p<0.05 (when compared with 1 week)
There is no established standard dose for memantine in different studies investigating effects of memantine for various indications. Also to our knowledge there is no study in literature investigating effects of memantine on cognitive functions during sevoflurane or desflurane anesthesia. So we chose 20 mg/kg/day oral dose of memantine and after a 30 days period we aimed to achieve a plasma drug concentration. On the other hand due to lack of blood memantine plasma level measurement, we can’t make any implication regarding the sufficiency of drug dose.

We observed significant difference between RAM results of diabetic groups at first week versus second week. RAM results were significantly decreased at second week and this conclusion indicates negative effects of diabetes on cognitive functions. On the other hand RAM results measured at 3rd and 4th weeks in memantine treated groups were significantly increased and this result indicates positive effects of memantine on cognitive functions even in diabetic background.

Similar to results achieved in diabetic groups, we found higher RAM results in memantine treated sevoflurane/desflurane exposed groups than those measured in only inhalation anesthetic administered groups. We suggest that, this is an interesting and important result that indicates positive effects of memantine on POCD.

NMDA receptor antagonists are promising agents in pain management after finding of new evidences related with role of NMDA receptors among neuropathic pain mechanisms. Ketamine is the most commonly used agent however several side effects such as psychotomimetic, sedative and hallucinogenic effects limit use of ketamine. Memantine is a well-tolerated new agent and becomes a promising drug in pain management (18). Chen et al (19) investigated effects of three different NMDA receptor antagonist –neramexane, memantine (20 mg/kg/day) and gabapentin- on hyperalgesia and allodynia in streptozotocin induced diabetic rats. Three agents were administered subcutaneously via a mini-pump placed in the back of animals. Experiments were performed under 2-3% isoflurane anesthesia for 2 weeks. At the end of the study authors concluded that memantine and neramexane are effective agents against diabetic neuropathic pain.

Alexander et al. (20) induced neural injury via 60 minutes of stretching in mice (8-10 weeks) followed by memantine (20 mg/kg i.p.), mifepristone (50 mg/kg), corticosterone (1.5 mg/kg) administrations. They found increased allodynia in corticosterone treated group. In contrast memantine has prevented stress induced allodynia. In a case report by Hacworth et al. (21) positive effects of memantine (20-45 mg/kg/day) added to morphine (100 mg/day) has been reported in two soldiers with phantom pain. Authors concluded that memantine can be used as an adjuvant in pain management and maximum effect can be achieved dependent on early start of memantine treatment.

Grande et al. (22) reported a case of neuropathic pain arisen following metastatic spinal tumor resection. After a 1 month period of opioid infusion followed by ketamine infusion, authors discontinued infusion of two agents and started to administer a combination of memantine (20 mg/kg/day), methadone, gabapentin and naproxen. This regimen provided a 3 month pain-free period until the patients’ death. In another study Viletti et al. (23) investigated effects of three different NMDA receptor antagonist –neramexane, memantine (20 mg/kg/day) and gabapentin- on hyperalgesia and allodynia in streptozotocin induced diabetic rats. Three agents were administered subcutaneously via a mini-pump placed in the back of animals. Experiments were performed under 2-3% isoflurane anesthesia for 2 weeks. At the end of the study authors concluded that memantine and neramexane are effective agents against diabetic neuropathic pain.

We found that memantine -used in Alzheimer disease- produces positive effects on cognitive functions and pain management after sevoflurane and desflurane anesthesia. We suggest that memantine -when administered in patients with high POCD risk- can reduce POCD incidence. Future clinical studies are needed in order to evidence possible various effects of memantine on POCD and anesthesia.

CONCLUSION

We found that memantine -used in Alzheimer disease- produces positive effects on cognitive functions and pain management after sevoflurane and desflurane anesthesia. We suggest that memantine -when administered in patients with high POCD risk- can reduce POCD incidence. Future clinical studies are needed in order to evidence possible various effects of memantine on POCD and anesthesia.

Conflict of interest

No conflict of interest was declared by the authors.

REFERENCES

1. Smith PL, Newman SP, Ell PJ, et al. Cerebral consequence of cardiopulmonary bypass. Lancet 1986; 1: 823-5.
2. Işık B. Relationship between anesthesia and cognitive functions. Türkiye Klinikleri J Anest Reanim 2004; 2: 94-102.
3. Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paracetamol vs epidural blockade for thoracotomy -a systematic review and meta-analysis of randomized trials. Br J Anaesth 2006;96: 418-26.
4. Li ZG, Zhang W, Grunberger G, et al. Hipocampal neuronal apoptosis in type 1 diabetes. Brain Res 2002; 946 (2): 221-31.
5. Mobius H. Pharmacological Rationale for Memantine in Choronic Cerebral Hypoperfusion, Especially Vascular Dementia. Alzheimer Disease and Associated Disorders 1999; 13: 172-8.
6. Minkeviciene R, Banerjee P, Tanila H. Memantin Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease. J Pharmacol Exp Ther 2004; 311: 677-82.
7. Culmsee C, Junker V, Kremers W, et al. Combination Therapy in Ischemic Stroke: Synergistic Neuroprotective Effects of Memantine and Clenbuterol. Stroke 2004; 35: 1197-202.
8. Berrino L, Oliva P, Massimo F, et al. Antinociceptive effect in mice of intraperitoneal N-methyl-D-aspartate Receptor Antagonists in the Formalin Test. Eur J Pain 2003; 7:131-7.
9. Sinclair AJ, Allard I, Bayer A. Observations of diabetes care in long term institutional settings with measures of cognitive function and dependency. Diabetes Care 1997; 20: 778-84.
10. Dej J, Misra A, Desai NG, et al. Cognitive function in younger type II diabetes. Diabetes Care 1997; 20: 32-35.
11. Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer’s disease. J Am Geriatr Soc 1993; 41: 710-4.
12. Cottrell JE. We care, therefore we are: anesthesia-related morbidity and mortality: the 46th Rovenstine lecture. Anesthesiology 2008; 109: 377-88.
13. Eckenhoff RG, Johansson JS, Wei H, et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004;101:703-9.
14. Hanning CD, Blokland A, Johnson M, et al. Effects of repeated anaesthesia on central cholinergic function in the rat cerebral cortex. Eur J Anaesthesiol 2003; 20: 53-7.
15. McShane L, Areosa S, Minakaran N. Memantine for Dementia. The Cochrane Library 2009; 1: 1-43.
16. Wise LE and Lichtman AH. The competitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial arm maze memory task. Eur J Pharmacol 2007; 575: 98–102.
17. Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296(3):239–6.

18. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: review of preclinical data. Neuropharmacol 1999; 38: 735-67.

19. Chen SR, Samoriski G, Pan HL. Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. Neuropharmacology 2009; 57: 121-6.

20. Alexander JK, DeVries AC, Kigerl KA, et al. Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. Brain Behav Immun 2009; 23: 851-60.

21. Hackworth RJ, Tokarz KA, Fowler IM, et al. Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain. Anesth Analg 2008; 107(4): 1377-9.

22. Grande LA, O’Donnell BR, Fitzgibbon DR, et al. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg 2008; 107(4): 1380-3.

23. Viletti G, Bergamaschi M, Bassani F, et al. Antinociceptive Activity of the N-Methyl-D-aspartate Receptor Antagonist N-(2-Indanyl)-glycinamide Hydrochloride (CHF3381) in Experimental Models of Inflammatory and Neuropathic Pain. JPET 2003; 306:804–14.